JNJ Johnson & Johnson
Company Analysis
Latest News
J&J’s DePuy Synthes expands in India, weighing $20B sale or spinoff
DePuy Synthes, Johnson & Johnson’s orthopedics division, is establishing a new Global Capability Centre in Bangalore, India. The hub will focus on innovation...
Johnson & Johnson Announces Retirement of EVP of Innovative Medicine, Names Successor
Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire effective September 1,...
🔴 Johnson & Johnson is trading 3.6% down today on profit-taking and sector weakness
Johnson & Johnson is trading 3.6% down at $255.87 as the stock faces profit-taking after recent gains pushed shares toward record levels. • The decline comes...
🟢 Johnson & Johnson is trading 3.1% up today after $5.5B talc settlement announcement
Johnson & Johnson is trading 3.1% up today at $273.75 after announcing a $5.5 billion agreement to resolve outstanding ovarian talc litigation, removing a...
JNJ Reaches $5.5 Billion Agreement to Resolve Ovarian Talc Litigation
Johnson & Johnson announced it has reached an agreement to resolve the outstanding ovarian talc litigation. The comprehensive resolution is designed to address...
Johnson & Johnson's Oral Psoriasis Drug 'Icotyde' Recommended for EU Approval
A key committee of the European Medicines Agency (EMA) recommended marketing authorization for Johnson & Johnson's new drug, Icotyde. The Committee for...
Johnson & Johnson Myeloma Combo Cuts Progression Risk 89% in Phase 3
Johnson & Johnson reported positive topline results from the Phase 3 MonumenTAL-6 study for multiple myeloma. The trial evaluated a dual-antigen regimen...
Judge Casts Doubt on Evidence in 69,000 J&J Talc Lawsuits
A U.S. federal judge has raised significant doubts about the scientific evidence underpinning approximately 69,000 lawsuits alleging Johnson & Johnson's talc...
J&J Wins FDA Clearance for OTTAVA, Entering Competitive Surgical Robotics Market
Johnson & Johnson received U.S. Food and Drug Administration (FDA) De Novo authorization for its OTTAVA Robotic Surgical System. The system performs various...
Johnson & Johnson's second quarter 2026 revenue of $25.3B beats estimates as the company raises its full-year outlook.
Johnson & Johnson reported second quarter 2026 revenue of $25.31 billion, up 6.6% year-over-year, and adjusted EPS of $2.90, an increase of 4.7%. The results...
Johnson & Johnson Q2 2026 Earnings Preview: What Analysts Expect on July 15, 2026
For the second quarter of 2026, analysts expect Johnson & Johnson to report consensus revenue of $25.18 billion and adjusted EPS of $2.85, with the stock...
Johnson & Johnson's $45 Million Talc Verdict Upheld by Illinois Appellate Court
The Illinois Appellate Court upheld a $45 million verdict against Johnson & Johnson and its consumer-health spinoff, Kenvue. An original jury found that...
J&J Secures FDA Approval for Dual-Energy Cardiac Ablation Platform
Johnson & Johnson secured FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform. The system allows electrophysiologists to toggle between...
🟢 JNJ is trading 3.5% up today, driven by positive clinical trial results and a significant investment
• Shares are currently trading at $268.46, up 3.5%, rebounding sharply from the prior session’s decline. • Johnson & Johnson highlighted positive primary...
Johnson & Johnson Talc Lawsuit Ends in Mistrial as Jury Deadlocks
A Johnson & Johnson lawsuit in Los Angeles Superior Court ended in a mistrial after the jury failed to reach a unanimous verdict. Brad Yandell brought the...
🟢 JNJ soars 3.6% on positive EU drug recommendation and healthcare sector rotation
JNJ is trading 3.6% up at $253.75 today, driven by a positive recommendation from the European Medicines Agency (EMA) for an indication extension of its drug...
J&J Rejects Obesity Drug Market, Aiming for 2030 Cancer Leadership
CEO Joaquin Duato announced Johnson & Johnson will not develop GLP-1 drugs for the obesity market. The company will instead focus on sectors where it maintains...
Johnson & Johnson invests $1B in Florida, scaling ACUVUE production
Johnson & Johnson is investing over $1 billion to expand its vision care manufacturing and distribution operations in Jacksonville, Florida. The project will...
Johnson & Johnson Myeloma Combo Shows 89% Survival in Phase 3
Johnson & Johnson reported positive Phase 3 MonumenTAL-3 results for a combination therapy treating relapsed or refractory multiple myeloma. The study...
J&J eyes first-ever rare blood treatment approval after positive Imaavy data
Johnson & Johnson presented Phase 2/3 ENERGY study results for Imaavy (nipocalimab) at the European Hematology Association 2026 Congress. The therapy targets...